Background: The amyloid precursor protein (APP) is genetically associated with Alzheimer's disease (AD). Elucidating the function of APP should help understand AD pathogenesis and provide insights ...

The lead drug emerging from the biotech's Helicon platform is billed as a "first-and-only-in-class" direct TCF-blocking beta-catenin inhibitor, which FogPharma says has potential as a treatment ...

Overholtzer et al. also noticed that before internalization, cells establish E-cadherin–beta-catenin-mediated adherens junctions and the compaction of these junctions appears to directly mediate ...

Bergen, Norway, April 23, 2025 – Cytovation ASA, a clinical stage oncology company focused on the development of its first-in-class bifunctional peptide CY-101, announces that it has raised NOK62 ...